Donohue James J. 4

What Happened
James J. Donohue, a director of Acurx Pharmaceuticals (ACXP), received a stock option award covering 2,150 shares on April 20, 2026. The transaction is reported as a derivative award (transaction code A) with a reported price of $0.00; the grant itself did not involve an out‑of‑pocket purchase or sale. This is a director compensation grant rather than a buy or sell of existing shares.

Key Details

• Transaction date: 2026-04-20; Form 4 filed 2026-04-22 (timely filing).
• Transaction type: Award/Grant of derivative securities (options), 2,150 shares, reported price $0.00.
• Vesting: Per footnote, the options vest on April 20, 2027.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Award granted under the Issuer's Director Compensation Policy.
• Filing timeliness: Filed within the normal Form 4 window (not noted as late).

Context
This was an options grant (derivative award) that vests in one year—not an immediate exercise or sale. Such director compensation grants are common and do not, by themselves, indicate buying or selling pressure in the stock. Retail investors should note grants are typically intended as long‑term incentives and only become economically meaningful if options vest and are exercised in the future.